A Prospective, Randomized, Controlled, Multicenter Study of Kanglaite Injection for the Treatment of Cancer Cachexia
The purpose of the study is to explore the efficacy and safety of Kanglaite Injection in the treatment of patients with late-stage cancer cachexia.
Cancer Cachexia
DRUG: Kanglaite Injection
Body weight, 77days|Lean body mass, 77days
Progression-free survival rate (PFS), 77days|Eastern Cooperative Oncology Group score (ECOG), 77days|Quality of life score (QOL), 77days|Survival curve, 77days|Overall Survival (OS), 77days|Body Mass Index (BMI), 77days|Serum albumin, 77days|Serum Prealbumin, 77days|Serum Lactic Acid, 77days|Incidence of myelosuppression (%), 77days
The study is a multicenter, prospective, randomized controlled study. The planned sample size is 160 subjects. These subjects will be randomized (1:1) to treatment group (i.e., standard therapy plus Kanglaite Injection) or control group (i.e., standard therapy plus blank control). The study population includes the patients with non small cell lung cancer (adenocarcinoma), colorectal carcinoma and pancreatic carcinoma, who are complicated with cachexia.